期刊文献+

声门上喉鳞癌nm23H1、表皮生长因子受体表达及其与颈淋巴结转移和预后的关系 被引量:3

Expression of nm23H1,epidermal growth factor receptor in supraglottic carcinoma and their relationship with cervical lymph node metastasis and prognosis
下载PDF
导出
摘要 目的 :研究声门上喉癌中 nm23H1,表皮生长因子受体 (epidermal growth factor receptor,EGFR)表达及其与颈淋巴结转移和预后的关系。方法:回顾分析 77例声门上喉鳞癌和 23例癌旁正常喉粘膜标本。应用免疫组化技术研究 nm23H1,EGFR的表达。结果:声门上喉鳞癌中 nm23H1,EGFR的阳性表达率为 76.62%和 72.73%。声门上喉鳞癌和癌旁正常喉粘膜中 nm23H1和 EGFR表达具有显著差异( Objective: To investigate nm23H1, epidermal growth factor receptor (EGFR) expression in supraglottic carcinoma and their relationship with cervical lymph node metastasis and prognosis. Methods: A total of 77 cases of supraglottic squamous cell carcinomas (SGSCC) and 23 normal laryngeal mucosa near tumor were reviewed. Immunohistochemical technique was used to determine the expression of nm23H1 and EGFR. Their relationship with lymph node metastasis and prognosis of the patient was investigated retrospectively. Results: The positive rate of nm23H1 and EGFR in SGSCC was 76.62% and 72.73% respectively. There was significant difference between SGSCC and normal laryngeal mucosa near tumor (P
出处 《癌症》 CSCD 北大核心 2000年第10期905-908,共4页 Chinese Journal of Cancer
关键词 NM23H1 EGFR 声门上喉鳞癌 颈淋巴结转移 nm23H1 Epidermal growth factor receptor Supraglottic neoplasms Cervical lymph node metastasis Prognosis
  • 相关文献

参考文献1

二级参考文献1

  • 1Yoshihisa Umekita,Nobumasa Enokizono,Yoshiatsu Sagara,Kazumi Kuriwaki,Takashi Takasaki,Aichi Yoshida,Hiroki Yoshida. Immunohistochemical studies on oncogene products (EGF-R, c-erbB-2) and growth factors (EGF, TGF-α) in human breast cancer: their relationship to oestrogen receptor status, histological grade, mitotic index and nodal status[J] 1992,Virchows Archiv A Pathological Anatomy and Histopathology(4):345~351

共引文献6

同被引文献30

  • 1Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to Gefitinib therapy. Science, 2004, 304 (5676) : 1497-1500.
  • 2Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. N Engl J Med, 2004, 350 (21) : 2129-2139.
  • 3Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. EurJCancer, 2001, 37 (S4) : S9-S15.
  • 4Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 2003, 21 (14) : 2787-2799.
  • 5AI-Hazzaa A, Bowen ID, Randerson P, et al. The effect of ZD1839 (Iressa) , an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15cells. Cell Prolif, 2005, 38 (2) : 77-86.
  • 6Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. JClinOncol, 2003, 21 (10) : 1980-1987.
  • 7Lee EJ, Whang JH, Jeon NK, et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism. Ann NYAcad Sci, 2007, 1095 (1) : 113-128.
  • 8Wirth LJ, Haddad R1, Lindeman NI, et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol, 2005, 23 (28) : 6976-6981.
  • 9CohenEE, LingenMW, VokesEE. The expanding role ofsystemic therapy in head and neck cancer. J Clin Oncol, 2004, 22 (9) : 1743-1752.
  • 10Magne N, Fischel JL, Tiffon C, et al. Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa') and cisplatin/ 5-fluorouracil. BrJCancer, 2003, 89 (3): 585-592.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部